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Abstract 
 
Drugs targeting the immune system such as corticosteroids, antihistamines and 
immunosuppressants have been widely exploited in the treatment of inflammatory, allergic 
and autoimmune disorders during the second half of the 20th century. The recent advances in 
immunopharmacological research made available new classes of clinically relevant drugs. 
These , compriseing protein kinase inhibitors and biologics, such as monoclonal antibodies 
that selectively modulate the immune response not only in cancer and autoimmunity but also 
in a number of additional human pathologies. Likewise, more effective vaccines utilising 
novel antigens, adjuvants and routes of administration are valuable tools for the prevention of 
transmissible infectious diseases and in allergen immunotherapy. Consequently, 
immunopharmacology is presently considered as one of the expanding fields of 
pharmacology. It , addressesing the selective regulation of immune responses and aimsing to 
uncover and exploit beneficial therapeutic options for typical and non-typical immune 
system-driven unmet clinical needs. While in the near future a number of new agents will be 
introduced, improving effectiveness and safety of those currently used is imperative for all 
researchers and clinicians working in the fields of immunology, pharmacology and drug 
discovery. The newly formed ImmuPhar (http://iuphar.us/index.php/sections-
subcoms/immunopharmacology) is the Immunopharmacology Section of the International 
Union of Basic and Clinical Pharmacology (IUPHAR, http://iuphar.us/). ImmuPhar provides 
a unique international expert-lead platform aiming to dissect and promote the growing 
understanding of immune (patho)physiology. Moreover, it  as well as to challenges the 
identification and validation of drug targets and lead candidates for the treatment of many 
forms of debilitating disorders, including, among others, cancer, allergies, autoimmune and 
metabolic diseases. 
 
 
  
Feldfunktion geändert
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Abbreviations 
 
Abl, Abelson kinase; AFPL, Neisseria meningitidis B proteoliposome; Akt, serine/threonine 
kinase Akt; ALK, anaplastic lymphoma kinase; APC, antigen-presenting cell; Bcr, breakpoint 
cluster region; Btk, Bruton typosine kinase; CD, cluster of differentiation; c-Kit, mast/stem 
cell growth factor receptor; CpG, unmethylated motifs of bacterial DNA; CTB, cholera toxin 
subunit B; CTLA, cytotoxic T lymphocyte antigen; D.P.T, diphteria, pertussis and tetanus; 
DS, delivery system; EGFR, epidermal growth factor receptor; EPH, ephrin kinase; Fab, 
fragment antigen-binding; FGFR, fibroblast growth factor receptor; GPCR, G protein-coupled 
receptor; GSK, Glaxo Smith Kline; HAV, hepatitis A virus; HBV, hepatitis B virus; HER, 
human epidermal growth factor receptor; HGFR, hepatocyte growth factor receptor; HiB, 
Haemofilus influenzae B antigen; HPV, human papilloma virus; HxNx, influenza virus; Ig, 
immunoglobulin; IFN, interferon; IL, interleukin; IPV, inactivated polio virus; IRAK, 
interleukin-1 receptor-associated kinase; IS, preferentially activated immune response; 
IUPHAR, International Union of Basic and Clinical Pharmacology; JAK, Janus kinase; LPS, 
lipopolysaccharide; mAbs, monoclonal antibodies; MAMP, microbial-associated molecular 
pattern; MEK, mitogen activated kinase kinase; MET, mesenchymal epithelial transition 
factor or hepatocyte growth or scatter factor receptor; MPL, monophosphoryl lipid; mTOR, 
mammalian target of rapamycin; NSAIDs, nonsteroidal anti-inflammatory drugs; ODN, 
oligodeoxynucleotide; PAMP, pathogen-associated molecular pattern; PDGF, platelet derived 
growth factor; PDGFR, platelet derived growth factor receptor; PI3K, phosphatidylinositol-3-
kinase; PK, protein kinase; PKI, protein kinase inhibitor; PRR, pattern recognition receptor; 
R, receptor; RA, rheumatoid arthritis; Raf, rapidly accelerated fibrosarcoma; RET, receptor 
for GDNF-family ligands; ROR, retinoic acid receptor-related orphan receptor; SCF, stem cell 
factor; Src, proto-oncogene tyrosine-protein kinase Src; STAT, signal transducer and activator 
of transcription; Syk, spleen tyrosine kinase; Th, T helper cell; TK, tyrosine kinase; TLR, toll-
like receptor; TNF, tumor necrosis factor; Treg, regulatory T cells; TrkB, tropomyosin 
receptor kinase B; VEGFR, vascular endothelial growth factor receptor; VLP, virus like 
particles; WHO, World Health Organization  
4 
 
Introduction 
 
For more than 50 years, drugs targeting immune cell pathways and receptors have been 
extensively exploited in the treatment of inflammatory, allergic and autoimmune disorders, 
and in preventing rejection following organ transplantation. Among them, many nonsteroidal 
anti-inflammatory drugs (NSAIDs), antihistamines, corticosteroids and immunosuppressant 
agents (Figure 1) have reached blockbuster status and are even included in the list of essential 
medicines of the World Health Organization (WHO, 2013).  
 
 
Figure 1  
Common clinically relevant drugs used in the treatment of human inflammatory, allergic and 
other immune system associated disorders. 
 
In recent years, several notable changes in our understanding and appreciation of the 
immune system, greater knowledge of the activity of agents that modify the immune 
responses and the significant biotechnological advances made available new classes of drugs. 
, For instance, including protein kinase inhibitors (PKIs) and biologics, such as monoclonal 
antibodies (mAbs) (Figure 1) that are capable of selectively modulating immune cell subsets 
(Dollery, 2014). At the same time, growing evidence connected the majority of human 
pathologies to dysfunctions of the innate and adaptive immune systems (Figure 2). Thus, 
scientists and clinicians working in universities and industry have shown enormous interest in 
the interrelationship between the disciplines of pharmacology and immunology, including 
immunotoxicology and immunogenetics (Cohen, 2006). Despite the use of vaccines and 
immunomodulating agents in clinical practice for many years, immunopharmacology is 
presently considered as one of the youngest fields of pharmacology. Immunopharmacology 
addresses the selective up- or down-regulation of immune responses, It  and aims to uncover 
and exploit more effective and safer therapeutic options for unmet clinical needs for a 
continuing expanding range of pathologies, such as cancer and inflammatory, infectious, 
immune and metabolic diseases. 
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Figure 2  
Examples of human pathologies linked to inflammation and to dysfunctions of the immune 
system. 
 
The importance of this area of pharmacology is evidenced by the recently launched 
ImmuPhar (Figure 3), the Immunopharmacology Section of the International Union of Basic 
and Clinical Pharmacology (IUPHAR Immunopharmacology Section, 2015). The main 
objective of ImmuPhar is to encourage the international cooperation and knowledge 
dissemination in immunopharmacology. The  through the activities are organized by the 
Executive Committee, the International Advisory Board, and the sub-committees on 
‘molecular targets for immunodulatory drugs’ (molecular oriented), ‘targets in immune-
related diseases’ (disease oriented), and ‘antibodies as therapeutics’.  
 
 
Figure 3  
Logo of ImmuPhar, the Immunopharmacology Section of the International Union of Basic 
and Clinical Pharmacology (IUPHAR). ImmuPhar aims to promote the international 
cooperation and knowledge dissemination in the growing field of immunopharmacology.  
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The objectives of ImmuPhar will be achieved by (a) stimulating world-wide research in 
basic and clinical immunopharmacology, (b) promoting high scientific and ethical standards 
in research into related medicines and therapeutics, (c) encouraging related scientific 
meetings, workshops and courses in different parts of the world, (d) improving and 
harmonising teaching of Immunopharmacology, (e) supporting the utilisation of 
immunopharmacological agents in health care delivery, particularly in developing countries, 
(f) evaluating patients experiencing adverse drug reactions by utilising clinical 
immunopharmacology skills, (g) encouraging collaboration with other agencies and 
organisations interested in the study, development and rational use of 
immunopharmacological agents, (h) exchanging and disseminating information on the safety 
and pharmacovigilance of related medicines and therapeutics, (i) fostering cooperative efforts 
among educational, research, clinical, industrial and governmental personnel engaged in 
activities relevant to the translational research in immunopharmacology. Membership to the 
Section is open to pharmacologists, immunopharmacologists, clinical pharmacologists, 
pathologists, immunologists and clinicians interested in the interrelationships between 
pharmacology and immunology. ImmuPhar works in close collaboration with the IUPHAR 
Committee on Receptor Nomenclature and Drug Classification (IUPHAR/BPS Guide to 
Pharmacology, 2015), while IUPHAR member societies and their sections are also eligible for 
affiliation.  
This review aims to summarize the new concepts on the role of immunopharmacology in 
the ongoing innovation in immunomodulatory drug development, from small molecules to 
vaccines and other biological modifiers. Moreover, due to the increasing number of PKIs and 
mAbs that enter the clinic, the challenge of both academic and industrial audiences is to 
consider the complex pharmacological profile of these novel options during drug 
development, without excluding the important advances in the pharmacology of classical 
therapeutic approaches. 
 
 
Small molecules - signaling bias - personalized medicine  
 
Despite the emergence and the clinical success of biologics, several limitations hamper the 
therapeutic manipulation of the inflammatory networks underlying the multifaceted aetiology 
of many immune disorders. For instance, agents produced by means of biological processes 
frequently involving recombinant DNA technology are expensive, and more importantly, lack 
oral availability and often show inefficient delivery to target tissues in vivo (Kopf et al., 
2010). By controlling signaling pathways implicated in tissue-specific inflammation, small 
molecules remain an effective approach to immunomodulatory drug development and 
repurposing (Thomson et al., 2009; Sundberg et al., 2014). Related emerging data confer new 
properties to old medications, as is the case with glucocorticoids or the immunosuppressive 
drug rapamycin. Besides the potent inhibition of growth factor-induced T cell proliferation, 
the serine/threonine protein kinase (PK) mammalian target of rapamycin (mTOR) has been 
reported to play an important role in the regulation of diverse functions of various immune 
cells (Thomson et al., 2009). Another example isMoreover, the dissection of the physiological 
relevance of the recently recognized rapid onset and short duration of the non-genomic 
glucocorticoid actions. These promise to facilitate the development of new improved 
strategies for the management of inflammatory and autoimmune diseases (Alangari, 2010; 
Simon et al., 2013).  
On the other hand, the latest advances in mast cell-derived mediator research, including 
histamine (Zampeli and Tiligada, 2009; Tiligada, 2012) and prostaglandins (Woodward et al., 
2011) are illustrative examples of the existing challenge to identify and validate new targets 
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and to optimize lead candidates for the treatment of many forms of diseases, such as asthma 
and, allergies, dermatitis and arthritis (Schumacher et al., 2014; Chliva et al., 2015; 
Kyriakidis et al., 2015). In particular, histamine interacts with four types of G protein-coupled 
receptors (GPCRs), designated as H1-H4, and it is a major component of the immune system 
playing a critical role in inflammation (Parsons and Ganellin, 2006). For more than 70 years, 
histamine has been one of the most exploited substances in medicine, providing blockbuster 
drugs acting on H1 and H2 receptors for the treatment of allergies and gastric ulcers, 
respectively (Parsons and Ganellin, 2006). Yet, the continuing appreciation of the 
pharmacodynamic and pharmacokinetic diversity of antihistamines targeting the H1 receptor 
reflects the ongoing efforts to modulate receptor activity and to translate preclinical drug 
actions into promising therapies for pathologies with high economic and societal impact (del 
Cuvillo et al., 2006; Schumacher et al., 2014). Interestingly, the discovery of the high affinity 
histamine H4 receptor in 2000 and its constitutive activity and expression mostly on cells of 
the immune system (Figure 4) revealed new concepts on the extensive biological functions of 
histamine. Besides its putative role in allergy, and exposed attractive perspectives for the 
translational potential of this new drug target in acute and chronic inflammation, host defense 
and neuropathic pain exposes attractive novel perspectives (Tiligada et al., 2009; Zampeli and 
Tiligada, 2009; Tiligada, 2012; Kyriakidis et al., 2015).  
 
 
Figure 4  
The histamine H4 receptor is expressed in various cell types and mediates a variety of distinct 
effects depending on the endogenous complement of receptor expression and signal 
transduction pathways upon binding of histamine, unbiased or biased ligands. 
 
 
In parallel to tThe rapid entry of H4 receptor-targeting compounds into advanced clinical 
development will in order to benefit patients with poorly treatable chronic diseases. 
Moreover, the pluridimensional, rather than the linear pharmacological efficacy of H4 receptor 
ligands (Figure 4) represents a paradigm of the recently described concept of ‘biased 
agonism’ or functional selectivity for GPCRs (Nijmeijer et al., 2013). GPCRs account for 
more than 65% of the medicines marketed today, highlighting their relevance in human 
(patho)physiology including immune responses (Rask-Andersen et al., 2011). By realizing the 
distinct functional outcomes of GPCR-mediated activation of complex signaling networks 
upon agonist binding, biased ligands represent an opportunity for the discovery of new drugs 
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with specific on-target efficacy and fewer on-target side effects (Kenakin and Christopoulos, 
2013). Taken together, the advances in these fields of research suggest that the differential 
expression and/or the selective modulation of receptor activity can alter pro- and anti-
inflammatory signals orchestrating acute and chronic inflammation reflected by the repertoire 
of immune cells and mediators (Zampeli and Tiligada, 2009; Tiligada, 2012; Nijmeijer et al., 
2013; Corbisier et al., 2015).  
Besides the efforts to advance the rational design of selective drugs targeting immune cell 
receptors that exhibit signaling bias (Nijmeijer et al., 2013; Corbisier et al., 2015) and to 
optimally translate the findings from experimental animals to human pathophysiology 
(Siebenhaar et al., 2015), attention has also been drawn to the links between genetic, 
epigenetic and non-genetic factors and their role in disease susceptibility and progression 
(Almouzni et al., 2014). Furthermore, a personalized approach to immune-driven pathologies, 
such as asthma requires the reclassification of diseases along causal pathways (Holgate, 
2013). The application of the ‘omic’ technologies to biological samples obtained from deeply 
phenotyped patients is likely to identify novel pathways shared with many diseases and to 
effectively repurpose therapeutics, thus offering entirely new avenues and solutions to major 
problems in immunopharmacology (Holgate, 2013).  
 
 
Protein kinase inhibitors 
 
The family of PKs includes 2 major subfamilies, the serine/threonine kinases and the tyrosine 
kinases (TKs). PKs are components of signal transduction pathways involved in diverse 
biological processes. They, such as cell growth, metabolism, differentiation and apoptosis, 
and  are now linked either directly or indirectly to more than 400 human diseases ranging 
from cancer to inflammatory, metabolic and cardiovascular disorders (Steinman et al., 2012; 
Fabbro, 2014; Fabbro et al., 2015; Galuzzi et al., 2015). There are more than 500 kinases in 
the human genome and as 30% of the proteome is phosphorylated, the modulators will have a 
vast pharmacology. Being responsible for important (patho)physiological functions,Thus, PKs 
constitute multiple targets for anticancer treatments and potentially for the modulation of 
inflammation and immunity if safety can be assured (Marfe and Di Stefano, 2014; Galuzzi et 
al., 2015).  
PKIs are usually small, cell-permeant molecules, which bind to the ATP-binding region 
of receptor and non-receptor kinases (Table 1). There are currently 39 marketed drugs acting 
on kinases and more than 130 in phase II/III ongoing clinical trials since the approval of the 
first PKI, imatinib, in 2001 (Nagar et al., 2002; Fabbro et al., 2015). PKIs have potentiated 
and sometimes replaced the therapy with mAbs.  usually directed against the extracellular 
domains of PK receptors. Whereas kinase inhibitors are validated in certain types of cancer, 
the situation is far from clear in autoimmune and inflammatory diseases. PKIs are designed to 
have a single or limited number of primary targets, however most of them might interact with 
more than one PK and they can exhibit significant cross-reactivity (Table 1). In fact, among 
the drugs approved for clinical use, only few, including lapatinib and imatinib are highly 
selective, while the majority inhibiting more than 10 and up to more than 100 kinases. The 
non-specificity of the target together with new and still unknown molecular mechanisms may 
be responsible for unexpected off-target mechanisms and side effects including drug 
resistance that may occur after long-term therapy (Davies et al., 2000; Ubersax and Ferrell, 
2007; Loriot et al., 2008; Chen and Fu, 2011).  
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Table 1 
Examples of protein kinase inhibitors and cancer therapy 
 
Drug Molecular target Tumor  
Imatinib  PDGFR, PDGF, SCF, c-Kit, Bcr-Abl Chronic myeloid leukemia, 
gastrointestinal stromal tumors 
Gefitinib  EGFR Metastatic non-small cell lung 
cancer 
Erlotinib  HER2, EGFR Metastatic non-small cell lung 
cancer 
Sorafenib  VEGFR-2,VEGFR-3, PDGFR-B, c-Kit, 
Fit-3 
Renal cell carcinoma 
Sunitinib  PDGFR, VEGFR, c-Kit, Fit-3 Renal cancer, gastrointestinal 
stromal tumors 
Dasatinib  Bcr-Abl, Src, c-Kit, EPH, PDGFR-B Imanitib-resistant chronic myeloid 
leukemia 
Nilotinib  PDGFR, c-Kit, Bcr-Abl Chronic myeloid leukemia 
Lapatinib  HER2, EGFR Brest cancer 
Crizotinib  ALK, HGFR ALK-positive lung cancer 
Ruxolitinib  JAK Myelofibrosis 
Vandetanib  RET, VEGFR2, EGFR Thyroid cancer 
Cabozantinib  RET, MET, VEGFR, c-Kit, TrkB Thyroid cancer 
Bosutinib  Bcr-Abl, Src  Chronic myeloid leukemia 
Dabrafenib  Raf  Melanoma 
Trametinib  MEK Metastatic cutaneous melanoma 
Nintedanib  VEGFR, FGFR, PDGFR Idiopathic pulmonary fibrosis 
Abl, Abelson kinase; ALK, anaplastic lymphoma kinase; Bcr, breakpoint cluster region; c-Kit, 
mast/stem cell growth factor receptor; EGFR, epidermal growth factor receptor; EPH, ephrin kinase; 
FGFR, fibroblast growth factor receptor; HER, human epidermal growth factor receptor; HGFR, 
hepatocyte growth factor receptor; JAK, Janus kinase; MEK, mitogen activated kinase kinase; MET, 
mesenchymal epithelial transition factor or hepatocyte growth or scatter factor receptor; PDGF, 
platelet derived growth factor; PDGFR, platelet derived growth factor receptor; Raf, rapidly 
accelerated fibrosarcoma; RET, receptor for GDNF-family ligands; SCF, stem cell factor; Src, proto-
oncogene tyrosine-protein kinase Src; TrkB, tropomyosin receptor kinase B; VEGFR, vascular 
endothelial growth factor receptor. 
 
 
PKI specificity has been tested in vitro with binding affinity and activity inhibition tests 
detecting also, if the entire kinase is used,  allosteric bindings and allosteric modulation of TK 
activity. In vitro assays have a number of limitations due, for example, to ATP concentration 
or lack of post-translational target modifications or of , other regulatory proteins and non-
kinase targets in the assay that are often responsible for relevant off-target effects (see Fabbro 
et al., 2015). Recent progresses in quantitative proteomics allow more impartial interpretation 
on PKI specificity and provide models PKI-PK interaction in the biological context. 
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Furthermore, pharmacokinetic characteristics such as absorption, (re)distribution, metabolism 
and elimination, as well asand  the possible interaction with drugs modulating their 
metabolism through cytochrome P450 isoenzymes are as important as the pharmacodynamic 
parameters and the choice of therapeutic target in order to assess the potential utility of PKIs 
(van Leeuwen et al., 2014).  
However, a more critical issue is the choice of therapeutic target (Table 2). The broad 
spectrum of PKI target interactions and the off-target effects are important not only to better 
understand the actual mechanism of action and the molecular basis of both acute and chronic 
adverse drug reactions, but also to define “secondary” therapeutic approaches that will permit 
in the future the use of those drugs in other diseases . For example, dasatinib, a breakpoint 
cluster region-Abelson kinase (Bcr-Abl) inhibitor, after approval for chronic myeloid 
leukemia, has been shown to strongly inhibit Bruton TK (Btk), important in diffuse large B-
cell lymphoma, thus opening to new therapeutic indications (Aalipour and Advani, 2013). 
Whereas kinase inhibitors are validated in certain types of cancer, the situation is far from 
clear in autoimmune and inflammatory diseases (Table 2). Testing a novel concept in this 
field is extremely expensive and the idea of pan-modulators working in multiple disorders is 
clearly incorrect. Indeed, Steinman et al. (2012) have powerfully argued that different 
strategies are needed for different diseases. Tumor necrosis factor (TNF) antagonists are 
active in rheumatoid arthritis (RA), and type 1 interferon modulators inactive, whereas in 
multiple sclerosis the converse is true and anti-CD20 therapies work in both (Steinman et al., 
2012). Moreover,B because of the ability of PKIs to bind TKs in the active or inactive 
conformation, sometimes they may activate rather than inhibit kinases (Moebitz and Fabbro, 
2012). The block in active conformation can explain in part the effect of some drugs that 
stabilize the phosphorylation state. In some cases, following drug binding, there is a kinase 
activation. This paradoxical effect which may be related to kinase interaction with molecules 
affecting the kinase conformational state can be part of drug action or even constitute a 
mechanism of resistance (Chen and Fu, 2011, Marfe and Di Stefano, 2014; Fabbro et al., 
2015).  
 
Table 2 
Targets that need to be validated for autoimmune and inflammatory diseases  
 
Target, inhibitors For which autoimmune diseases? 
• Akt 
• Multiple chemokine receptors 
• IFN α 
• IL 1 
• IL 6 
• IL 17 
• Inflammasome 
• IRAK4 
• JAK/STAT 
• mTOR 
• PI3K δ /γ 
• Syk 
• TLR 2/4/7/9 
• TNF α 
• ROR-γ 
• Asthma 
• Rheumatoid arthritis 
• Multiple sclerosis (IL 17+) 
• Aspects of schizophrenia 
• Juvenile diabetes 
• Cardiomyopathy 
• Antiphospholipid syndrome 
• Guillain-Barré syndrome 
• Crohn’s disease 
• Graves’ disease 
• Sjogren’s syndrome 
• Vitiligo 
• Myasthenia gravis 
• Systemic lupus erythematosus 
• Psoriasis 
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Akt, serine/threonine kinase Akt; IFN, interferon; IL, interleukin; IRAK, interleukin-1 receptor-
associated kinase; JAK, Janus kinase; mTOR, mammalian target of rapamycin; PI3K, 
phosphatidylinositol-3-kinase; ROR, retinoic acid receptor-related orphan receptor; STAT, signal 
transducer and activator of transcription; Syk, spleen tyrosine kinase; TLR, toll-like receptor; TNF, 
tumor necrosis factor 
 
 
Although PKIs share the same mechanism of action, competing with ATP to the catalytic 
site of the enzyme, they differ in specificity of target, pharmacokinetics and side effects. 
Major acute and chronic side effects, involving different organs, limit the clinical use and 
cause clinical trial suspension and drug withdrawal (Loriot et al., 2008). It is hoped that in the 
near future new PKIs that target new kinases can reach the preclinical and clinical trials. Thus, 
there is a real need for an expert-lead initiative to help drug discovery and development. 
IUPHAR has developed a database of all the kinases, with their main pharmacology 
(IUPHAR/BPS Guide to Pharmacology) and will be leading a major initiative on their role in 
immunopharmacology. 
 
 
Monoclonal antibody therapies  
 
Advances in basic immunology have contributed to identifications of various critical 
molecules involved in several immune reactions and their respective pathophysiological roles 
in a variety of immunological diseases. One of the most important key technical advances for 
promoting immunology research is the establishment of mAbs, led by the Nobel Prize 
laureates, Milstein and Köhler (Köhler and Milstein, 1975). Interestingly, generation of mAbs 
recognizing various specific targets, such as cell surface molecules and cytokines, 
accompanied with flow cytometrical methodology, has enabled us to respectively distinguish 
an increasing number of cellular subsets. This in turn has brought to recent explosive 
progresses of the immunology research field in identifying new potential drug targets 
(Thomas, 1989). 
mAbs neutralizing and inactivating target molecules/cells have been utilized for a while 
for treating several human diseases (Beck et al., 2010; Chan and Carter, 2010). For example, 
the initial trial was done by using rituximab, an anti-CD20 mAb, for treating B cell lymphoma 
by depleting CD20-expressing B-lineage cells (Reff et al., 1994). In the case of rheumatic 
diseases, a number of mAbs targeting tumor necrosis factor (TNF) are now frequently used 
for treating rheumatoid arthritis (RA), such as infliximab, adalimumab and golimumab 
(Breedveld, 2000; Feldmann and Maini, 2001). The development and clinical application of 
mAbs, so-called ‘biological agents’, have undoubtedly caused a paradigm shift in the 
therapeutics of RA. Besides TNF, several targets have been utilized to date, such as 
interleukin (IL) 6 and its receptor (tocilizumab), cytotoxic T lymphocyte antigen 4 (CTLA-4), 
and so on. In addition to RA, several immunological disorders are now targeted by mAb 
therapies, including multiple sclerosis (treated by alemtuzumab anti-CD52), inflammatory 
bowel diseases (anti-TNF mAbs), psoriasis (anti-IL17 mAbs), and asthma (omalizumab anti-
IgE) (Scalapino and Daikh, 2008; Pelaia et al., 19122012; Tanaka et al., 19122012), Some 
representative examples are illustrated in Table 23. 
One of the most remarkable advantages of mAb therapies is its high specificity for their 
targets, which would minimize off-target adverse effects. It is really surprising that depletion 
or inactivation of a single molecule by mAb alters cytokine cascade and blocks inflammatory 
responses in certain conditions. However, one should not disregard the challenges that 
therapeutic mAb therapy are raising, such as their immunogenicity, delivery only through 
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injection, the usually extremely long half-life etc. Nevertheless, recent bioengineering 
technology enabled us to develop less immunogenic mAbs, such as ‘chimera’ (having murine 
variable regions), ‘humanized’ (with murine complementary determining regions), or 
complete ‘human’ therapeutic mAbs. In addition to conventional mAbs, pegylated Fab portion 
of IgG, e.g. against TNF (certolizumab pegol) and a fusion protein of immunoglobulin (Ig) G 
Fc region with several targets, such as the extracellular domain of CTLA-4 (abatacept) or 
TNF receptor (etanercept), could also be used clinically. These and possibly other 
developments will facilitate the creation of less side-effects-prone mAbs and perhaps even 
patient-specific drugs (Breedveld, 2000; Beck et al., 2010; Breedveld, 2000). 
 
 
Table 23 
Representative examples of therapeutic monoclonal antibodies 
 
Molecule Name  Type  Disease target 
TNF Infliximab 
Adalimumab 
Golimumab 
Etenercept  
Certolizumab pegol 
Chimera  
Human 
Human 
TNFR-Ig 
Fab-pegosyl 
Rheumatoid arthritis, Crohn’s 
diseases, Behçet's disease 
CD20  Rituximab 
Ocrelizumab 
Ofatumumab 
Chimera 
Humanized 
Human 
B cell lymphoma, (vasculitis) 
IL6R Tocilizumab 
Sarimumab 
Humanized  
Human 
Rheumatoid arthritis 
CTLA4 Abatacept CTLA4-Ig Rheumatoid arthritis 
IL17 Secukinumab 
Ixekizumab 
Brodalumab 
Human  
Humanized  
Human  
Psoriasis 
CD52 Alemtuzumab Humanized Multiple sclerosis 
IgE Omalizumab Humanized Severe asthma 
CD, cluster of differentiation; CTLA, cytotoxic T-lymphocyte-associated protein; Fab, fragment 
antigen-binding; Ig, immunoglobulin; IL, interleukin; R, receptor; TNF, tumor necrosis factor. 
 
 
 
Vaccines and adjuvants 
 
Vaccines have had an enormous impact on human health and are likely the most important 
tool to prevent transmissible infectious diseases. There has been much development in the 
search for novel attenuated or inactivated microorganisms, various delivery viruses or 
particles; novel antigens, peptides or DNA; novel routes of administration (e.g. subcutaneous 
versus mucosal routes) and, more recently, novel adjuvants with known mechanisms of 
action. The discovery of pattern recognition receptors (PRRs) of innate immunity and their 
respective ligands, pathogen or microbial-associated molecular patterns (PAMPs or MAMPs) 
have literally boosted interest in the field (Song and Lee, 2012). Activation of PRRs, such as 
toll-like receptors (TLRs), stimulates immune responses when PAMPs are given with the 
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antigen in a proper delivery vehicle. Such receptors and delivery systems have thus received 
much attention for the development of novel adjuvants (Reed et al., 2009) (Table 34). The 
search for novel, local and long-acting selective agonists of TLRs is an area of particular 
interest to immunopharmacologists. In addition, there is much interest in understanding their 
exact mechanisms of action and potential local and systemic side effects. Custom-made 
adjuvants may enhance vaccine efficacy with significantly less side-effects. Another aspect of 
immunization that is of interest to immunopharmacology relates to the use of immunotherapy 
in the context of allergic diseases, largely concerning optimization of antigen dose, delivery 
route and mechanism of action. 
 
 
Table 34 
Adjuvants licensed for human prophylactic vaccines (Reed et al., 2009; Leroux-Roels, 2010)  
  
Adjuvants 
Mechanism of action 
Antigens (in vaccines) Manufacturer 
DS IS 
Alumminium salts   Th2 D.P.T, HBV, IPV, HiB, etc  Several 
Emulsion o/w MF59   Th1 H1N1 (Fluad™) 
H5N1 (Focetria™) 
Novartis 
Emulsion o/w AS03   Humoral (Th?) H5N1 (Prepandrix™), 
H1N1 (Arepanrix™) 
GSK 
Emulsion o/w AF03   Humoral (Th?) H1N1 (Humenza™)  Sanofi Pasteur 
MPL+Alum (AS04)   Th2/Th1 HBV (Fendrix™) 
HPV (Cervarix™) 
GSK 
RC529+Alum   Th1 HBV (Supervax™) Dynavax 
Virosomes   Th2/Th1 H5N1 (Inflexal™) 
HAV (Epaxal™) 
Crucell 
CTB*  - IgA? V. cholerae (Dukoral™) SBL 
*, the only mucosal adjuvant licensed in oral cholera vaccine; CTB, cholera toxin subunit B; D.P.T, 
diphteria, pertussis and tetanus; DS, delivery system; GSK, Glaxo Smith Kline; HAV, hepatitis A 
virus; HBV, hepatitis B virus; HiB, Haemofilus influenzae B; HPV, human papilloma virus; HxNx, 
influenza virus; Ig, immunoglobulin; IPV, inactivated polio virus; IS, preferentially activated immune 
response; MPL, monophosphoryl lipid A; Th, T helper cell; VLP, virus like particles.  
 
 
Several immune stimulator components from bacteria and viruses have been identified, 
including lipopolysaccharide (LPS) and unmethylated motifs of bacterial DNA (CpG), which 
can activate TLRs on the surface or in the cytosolic compartments of antigen-presenting cells 
(APCs) (Song and Lee, 2012). APC activation increases cytokine expression, antigen 
presentation, and other events causing the maturation of APCs. Activated APCs modulate the 
activation of T and B cells, as well as the commitment of CD4+ T cells in T helper cells Th1, 
Th2, Th17 and in regulatory T (Treg) cells (Zhu et al., 2010). Activation of TLR9 by CpG 
oligodeoxynucleotides (ODNs) inhibits a Th2 response and favors a Th1 pattern. The Th1 
pattern is characterized by induction of interferons and other cytokines which favors the 
elimination of bacteria and viruses, whereas Th2 pattern is elicited to eliminate parasitic 
infections and is also related with allergy reactions (Medzhitov, 2007). 
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Delivery systems are vehicles carrying antigens and also immune stimulators to APCs. 
Aluminum salts have been widely used in human vaccines and are an example of a depot 
adjuvant. A depot effect promotes the presentation of antigens to APCs, although Th2 
responses have been reported to be associated with stimulation of inflammasome signaling 
(Eisenbarth et al., 2008). For this reason, alum adjuvants have been used less in novel vaccine 
strategies. However, the combination of aluminum salts with potent immune stimulators, such 
as LPS, monophosphoryl lipid (MPL), or Neisseria meningitidis B proteoliposome (AFPL) 1 
may switch the Th2 response to a Th1 pattern (Moschos et al., 2006; Perez et al., 2007). Non 
depot adjuvant, like liposomes, emulsions and low size particles have been evaluated and are 
under development in new vaccine candidates (Leroux-Roels, 2010). 
Current prophylactic vaccines are administered parenterally and several disadvantages 
have been associated with this practice, such as the risk of injury and cross-infection through 
contaminated needles (Shah et al., 2005), the lack of potential for self-administration and the 
induction of mainly systemic immune response (Giudice and Campbell, 2006). Several 
researchers are working together to find proper delivery systems and immune-adjuvants to 
develop mucosal vaccines (Gebril et al., 2012).  
Regarding allergy, there are traditional vaccines developed from pollen, house dust mites, 
pets, molds, food, and insects, as well as improved allergen ones that use PAMPs and 
different delivery systems (Akkoc et al., 2011). An example is the use of detoxified LPS from 
Salmonella minnesota, known as MPL A, which has been evaluated with pollen allergens. 
MPL is thought to be a Th1-inducing adjuvant. Engagement of MPL with TLR4 in APCs 
stimulates the secretion of cytokines such as IL12, which is closely related to the reduced 
induction of IgE and switching to IgG1 and IgG4 in humans (Mothes et al., 2003). Pollinex 
Quatro™, licensed in Europe and Canada, contains MPL and is used for the treatment of 
allergy to grass, tree, or ragweed pollen (Patel et al., 2006).  
 
Summary and conclusions 
 
In addition to the classical therapeutic approaches, the novel immunopharmacological 
concepts and tools and their relevance to human disease offer new options for unmet medical 
needs including cancer, inflammatory, autoimmune, metabolic and infectious diseases among 
others. The recent developments in immunology and pharmacology emphasize the necessity 
not only to exploit new classes of drugs, such as cytokines, PKIs and mAbs, targeting the 
modulation of decisive immune responses for a range of human pathologies, but also to 
improve those that are already in use. The optimal translation of experimental data 
(Siebenhaar et al., 2015), the characterization of the links between genetic, epigenetic and 
non-genetic factors (Almouzni et al., 2014) and the application of the ‘omic’ technologies are 
likely to identify novel disease pathways and to repurpose a number  of therapeutics (Holgate, 
2013). While in the near future a number of new agents will be introduced, the common 
challenge for all researchers and clinicians working in the fields of immunology, 
pharmacology and drug development is to improve efficacy and safety of the diverse classes 
of drugs discussed herein. The newly formed ImmuPhar is the Immunopharmacology Section 
of the IUPHAR that provides a unique international expert-lead platform to dissect and 
promote the growing knowledge and understanding of immune (patho)physiology and its 
exploitable modification by a variety of medicines.  
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